Hanna Thorsson
YOU?
Author Swipe
View article: The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes Open
Acute myeloid leukemia is a genetically and cellularly heterogeneous disease. We characterize 120 AMLs using genomic and transcriptomic analyses, including single-cell RNA sequencing. Our results reveal an extensive cellular heterogeneity …
View article: Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia
Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia Open
Immunotherapy has shown limited success in acute myeloid leukemia (AML), indicating an incomplete understanding of the underlying immunoregulatory mechanisms. Here we identify an immune evasion mechanism present in 60% of AML cases, wherei…
View article: The cellular state space of AML unveils novel <i>NPM1</i> subtypes with distinct clinical outcomes and immune evasion properties
The cellular state space of AML unveils novel <i>NPM1</i> subtypes with distinct clinical outcomes and immune evasion properties Open
Acute myeloid leukemia (AML) is a genetically and cellularly heterogeneous disease. We characterized 120 AMLs using genomic and transcriptomic analyses, including single-cell RNA sequencing. Our results reveal an extensive cellular heterog…
View article: Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in <i>DUX4</i>-r cases
Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in <i>DUX4</i>-r cases Open
B-cell progenitor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy and is driven by multiple genetic alterations that cause maturation arrest and accumulation of abnormal progenitor B cells. Current treatment …
View article: The complement receptor C3AR constitutes a novel therapeutic target in <i>NPM1</i>-mutated AML
The complement receptor C3AR constitutes a novel therapeutic target in <i>NPM1</i>-mutated AML Open
Mutated nucleophosmin 1 (NPM1) is the most common genetic alteration in acute myeloid leukemia (AML), found in ∼30% of cases. Although mutations in this gene are considered favorable according to current risk stratification guidelines, a l…
View article: Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin
Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin Open
The glycosaminoglycan dermatan sulfate (DS) is a well-known activator of heparin cofactor II-dependent inactivation of thrombin. In contrast to heparin, dermatan sulfate has never been prepared recombinantly from material of non-animal ori…